DOGWOOD THERAPEUTICS INC. - COMMON STOCK

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

21 1 2025 09:15:00 提供 Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

18 11 2024 08:45:00 提供 Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

07 11 2024 07:05:00 提供 Nasdaq GlobeNewswire

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

31 10 2024 09:15:00 提供 Nasdaq GlobeNewswire

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

30 10 2024 09:15:00 提供 Nasdaq GlobeNewswire